Balam, Saidou and Jafarshad, Ali and Servis, Catherine and Frank, Geraldine and Reed, Steve and Pink, Richard and Druilhe, Pierre and Spertini, Francois and Corradin, Giampietro (2016) Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice. VACCINE, 34 (13). pp. 1566-1574. ISSN 0264-410X, 1873-2518
Full text not available from this repository. (Request a copy)Abstract
Background: Plasmodium falciparum MSP2 is a blood stage protein that is associated with protection against malaria. It was shown that the MSP2 dimorphic (D) and constant (C) regions were well recognized by immune human antibodies, and were characterized by major conserved epitopes in different endemic areas and age groups. These Abs recognized merozoite-derived proteins in WB and IFA. Here, the goal was to determine in mice the immunogenicity of the two allelic MSP2 D and C domains formulated with different adjuvants, for their possible use in future clinical studies. Method: Female A/J, C3H, and ICR mice were immunized subcutaneously 3 times at 3-week interval with a mixture of allelic and conserved MSP2 long synthetic peptides formulated with different adjuvants. One week after the third injection, sera from each group were obtained and stored at 20 C for subsequent testing. Results: Both domains of the two MSP2 families are immunogenic and the fine specificity and intensity of the Ab responses are dependent on mouse strains and adjuvants. The major epitopes were restricted to the 20-mer peptide sequences comprising the last 8 aa of D and first 12 aa of C of the two allelic families and the first 20 aa of the C region, this for most strains and adjuvants. Strong immune responses were associated with GLA-SE adjuvant and its combination with other TLR agonists (CpG or GDQ) compared to alhydrogel and Montanide. Further, the elicited Abs were also capable of recognizing Plasmodium-derived MSP2 and inhibiting parasite growth in ADCI. Conclusion: The data provide a valuable opportunity to evaluate in mice different adjuvant and antigen formulations of a candidate vaccine containing both MSP2 D and C fragments. The formulations with GLA-SE seem to be a promising option to be compared with the alhydrogel one in human clinical trials. (C) 2016 Elsevier Ltd. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MEROZOITE SURFACE PROTEIN-2; STAGE MALARIA VACCINE; PAPUA-NEW-GUINEA; IMMUNE-RESPONSES; HUMORAL RESPONSE; ENDEMIC AREA; PROTECTION; PEPTIDES; SAFETY; CANDIDATES; P. falciparum; MSP2; Dimorphic region; Constant region; Immunogenicity; Adjuvant |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 03 Apr 2019 11:29 |
| Last Modified: | 03 Apr 2019 11:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3238 |
Actions (login required)
 |
View Item |
